2021³â Á¦34ȸ ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ Á¤±âÇмú´ëȸ ¹× ÃÑȸ : 2021-08-28±³À°ÀÏÀÚ : 2021-08-28
±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ
±³À°ÁÖÁ¦ :
2021³â Á¦34ȸ ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ Á¤±âÇмú´ëȸ ¹× ÃÑȸÁÖÃÖ±â°ü : ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ
´ã´çÀÚ : ±èÀºÁÖ
¿¬¶ôó : 02-704-8574
À̸ÞÀÏ :
app@app2010.com ±³À°Á¾·ù : ºñ´¢ÀÇÇаú
Âü¼®¿¹»óÀοø : 50¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
±¤ÁÖ±¤¿ª½Ã±³À°½Ã°£ : 5 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í * ¼±Âø¼ø 50¸í ¸¶°¨ (Á¶±â ¸¶°¨ µÉ ¼ö ÀÖ½À´Ï´Ù.)* ÇöÀåµî·ÏÀº ¾ø½À´Ï´Ù.
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 08-28 4Ãþ ÄÁº¥¼ÇȦ 08:30~09:00 Registration ()
±âŸ 08-28 4Ãþ ÄÁº¥¼ÇȦ 09:00~09:05 President¡¯s Welcome ()
±âŸ 08-28 4Ãþ ÄÁº¥¼ÇȦ 09:05~09:10 Congratulatory Remark ()
±³À°½Ã°£ 08-28 4Ãþ ÄÁº¥¼ÇȦ 09:10~10:00 Podium Session I: Prostate Cancer ()
±³À°½Ã°£ 08-28 4Ãþ ÄÁº¥¼ÇȦ 10:00~10:20 Paradigm shifts in the management of patients with prostate cancer Àü¼º¼ö(¼º±Õ°üÀÇ´ë)
ÈÞ½Ä 08-28 4Ãþ ÄÁº¥¼ÇȦ 10:20~10:40 Break ()
±³À°½Ã°£ 08-28 4Ãþ ÄÁº¥¼ÇȦ 10:40~10:55 Diagnostic and therapeutic role of pelvic lymph node dissection in men with prostate cancer/Pros ±èų²(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 08-28 4Ãþ ÄÁº¥¼ÇȦ 10:55~11:10 Diagnostic and therapeutic role of pelvic lymph node dissection in men with prostate cancer/Cons °¼º±¸(°í·ÁÀÇ´ë)
±³À°½Ã°£ 08-28 4Ãþ ÄÁº¥¼ÇȦ 11:10~11:25 Management of incidentally detected small renal mass in octogenarian patients/Active surveillance ¹Ú¿ëÇö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 08-28 4Ãþ ÄÁº¥¼ÇȦ 11:25~11:40 Management of incidentally detected small renal mass in octogenarian patients/Active treatment ±èÁ¤±Ç(¼¿ïÀÇ´ë)
±âŸ 08-28 4Ãþ ÄÁº¥¼ÇȦ 11:40~11:55 Çмú»ó ½Ã»ó ()
±âŸ 08-28 4Ãþ ÄÁº¥¼ÇȦ 11:55~12:10 ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ ⸳ 30Áֳ⠱â³ä½Ä ¹× 30Áֳ⠱â³äÃ¥ÀÚ ¹ß°£½Ä ()
½Ä»ç 08-28 4Ãþ ÄÁº¥¼ÇȦ 12:10~13:10 Lunch ()
±âŸ 08-28 4Ãþ ÄÁº¥¼ÇȦ 13:10~13:30 Project 2020 Report / 2021 Proposal ()
±³À°½Ã°£ 08-28 4Ãþ ÄÁº¥¼ÇȦ 13:30~13:50 Chimeric antigen receptor (CAR)-T cell therapy: Novel anti-cancer cell therapy ±è¼®Áø(¼º±Õ°üÀÇ´ë Ç÷¾×Á¾¾ç³»°ú)
±³À°½Ã°£ 08-28 4Ãþ ÄÁº¥¼ÇȦ 13:50~14:10 Current status and perspective of chimeric antigen receptor (CAR)-engineered naturalkiller cells Á¶´ö(¼º±Õ°üÀÇ´ë Áø´Ü°Ë»çÀÇÇаú)
±³À°½Ã°£ 08-28 4Ãþ ÄÁº¥¼ÇȦ 14:10~15:00 Podium Session II: Bladder Cancer ()
ÈÞ½Ä 08-28 4Ãþ ÄÁº¥¼ÇȦ 15:00~15:20 Break ()
±³À°½Ã°£ 08-28 4Ãþ ÄÁº¥¼ÇȦ 15:20~16:10 Podium Session III: Renal Cell Carcinoma ()
±³À°½Ã°£ 08-28 4Ãþ ÄÁº¥¼ÇȦ 16:10~16:30 Impact of COVID-19 on patients with urologic cancer ÃÖ¼¼¹Î(°æºÏÀÇ´ë)
±³À°½Ã°£ 08-28 4Ãþ ÄÁº¥¼ÇȦ 16:30~16:50 The new treatment paradigm, Immunotherapy in non-muscle invasive bladder cancer ¼ºÇöȯ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 08-28 4Ãþ ÄÁº¥¼ÇȦ 16:50~17:10 New therapeutic agents for non-metastatic castration resistant prostate cancer ÇÏÀ±¼®(°æºÏÀÇ´ë)
±âŸ 08-28 4Ãþ ÄÁº¥¼ÇȦ 17:10~17:40 Çмú»ó ½Ã»ó ¹× ÃÑȸ ()
±âŸ 08-28 4Ãþ ÄÁº¥¼ÇȦ 17:40~17:50 Æóȸ»ç ()